White Matter Lesion Volumes on 3-T MRI in People With MS Who Had Followed a Diet and Lifestyle Program for More Than

Mariaan Jaftha1,2, Frances Robertson2,3, Susan J van Rensburg4

  • 1Department of Medical Imaging and Therapeutic Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, Cape Town, South Africa.

PubMed

Insights

A pathology-supported genetic testing (PSGT) program, including lifestyle changes, significantly reduced white matter lesion (WML) volumes in people with multiple sclerosis (pwMS). This suggests interventions may slow disease progression in MS patients.

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Cerebral white matter lesion (WML) formation in multiple sclerosis (MS) is linked to oligodendrocyte death.
  • Current MS treatments aim to limit WML accumulation and disability.
  • A novel pathology-supported genetic testing (PSGT) program identified MS risk factors (deficiencies, aggravators) and developed mitigation strategies.

Purpose of the Study:

  • To assess if the PSGT Program can reduce or prevent WML formation in people with MS (pwMS).
  • A pilot case-control study was conducted over a 10-year period.

Main Methods:

  • 22 pwMS underwent baseline and 10-year follow-up MRI scans.
  • White matter lesion (WML) volumes were quantified using Sequence Adaptive Multimodal SEGmentation (SAMSEG) software.
  • Data included age, disease duration, disability status (EDSS), and medication.

Main Results:

  • PwMS adhering to the PSGT program (n=13) showed significantly smaller WML volumes (4950 ± 5303 mm³) compared to non-adherent pwMS (n=9) (17934 ± 11139 mm³; p=0.002).
  • WML volumes correlated significantly with disability (EDSS, p=0.02).
  • No significant association was found with age (p=0.350), disease duration (p=0.709), or Interferon-β treatment (p=0.70).

Conclusions:

  • Dietary and lifestyle modifications, guided by PSGT, may reduce cerebral WMLs in pwMS.
  • These interventions show potential for slowing MS disease progression.
  • Larger studies are needed to confirm the efficacy of these interventions in pwMS.